Pharmacogenetics in Practice: Case Studies & Considerations for Effective Implementation

Implementing and Scaling Pharmacogenetics

Pharmacogenetics (PGx) has the potential to achieve the practice of precision medicine, but challenges exist. Issues such as the lack of provider and patient education, the absence of clinical decision support, and unclear reimbursement are significant barriers to implementing PGx in a scalable manner.

In this webinar, you’ll examine several case studies that highlight the process of evaluating PGx reports and how they can be used in a clinical context. You’ll also review important considerations for providers to implement and scale PGx effectively.

Learning Objectives

This webinar will help you:

• Analyze the evaluation of PGx reports
• Clarify PGx report limitations
• Review how PGx reports can be used in a clinical context
• Identify factors for effectively implementing PGx in a clinical setting
• Discuss challenges to scaling PGx as a precision medicine tool and develop ways to address these challenges

Watch on Demand       Download Slides (PDF, 2.1MB)

For research use only. Not for diagnostic procedures.

Fisher Healthcare is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.™ Program. One P.A.C.E.™ credit-hour will be provided for this complimentary basic level program.

Jeremy Stuart, PhD, MPH (NRCC), Chief Scientific Officer and Laboratory Director at Precision Genetics

Dr. Jeremy Stuart has extensive experience in the life sciences industry. He specializes in commercial operations, technology development and transfer, manufacturing design, and start-up and analytical validation of laboratory-developed tests (LDTs).

He currently serves as chief scientific officer and laboratory director at Precision Genetics. Dr. Stuart was part of the senior management team that completed the management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF Diagnostics. At Selah, he led the development and validation of all molecular assays and oversaw clinical studies. Prior to Selah, he was a key member of the Agencourt Personal Genomics team, which was acquired by Thermo Fisher Scientific (then Applied Biosystems). Dr. Stuart was a co-developer of the Sequencing by Oligonucleotide Ligation and Detection (SOLiD) next-generation sequencing technology and co-authored several patents related to next-generation sequencing.

Before entering the life sciences industry, Dr. Stuart completed his postdoctoral work at the Department of Genetics & Complex Diseases at the Harvard School of Public Health. He earned his master’s degree in Toxicology from the University of Minnesota and his doctorate from Harvard University.